Harriet Edelman
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Assurant Launches Chile Protection Offering Amid Valuation Debate. Assurant announced a new protection offering in Chile, adding a new market to its portfolio. Analysts note that the stock has risen 20.1% over the past year, yet some view it as undervalued compared to a target of $330. The company also continues to expand in reinsurance and energy risk, while its dividend yield sits at 1.74%.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analysts Raise AIZN Price Target 13.72% to $19.99. Analysts have raised the consensus price target for Assurant's 2061 subordinated notes by 13.72% to $19.99, suggesting improving sentiment toward the insurer's credit outlook. The notes currently trade near support at $19.09 with an RSI of 28.6, indicating technical oversold conditions. This upward revision in price targets may reflect views that the notes are undervalued at current levels.
Transaction History
| EAT | ▲ Buy | Grant | 166 | $0 | 8/27/2026 | View on chart |
| AIZ | ▲ Buy | Grant | 668 | $0 | 5/22/2026 | View on chart |
| EAT | ▲ Buy | Grant | 283 | $0 | 5/14/2026 | View on chart |
| EAT | ▲ Buy | Grant | 238 | $0 | 2/12/2026 | View on chart |
| EAT | ▼ Sell | Open Market | 8,400 | $1.3M | 1/29/2026 | View on chart |
| EAT | ▲ Buy | Grant | 330 | $0 | 11/13/2025 | View on chart |
| EAT | ▲ Buy | Grant | 249 | $0 | 8/28/2025 | View on chart |
| EAT | ▼ Sell | Gift | 80 | $0 | 8/18/2025 | View on chart |
| EAT | ▼ Sell | Gift | 175 | $0 | 8/14/2025 | View on chart |
| EAT | ▼ Sell | Open Market | 8,325 | $1.3M | 8/14/2025 | View on chart |
| AIZ | ▲ Buy | Grant | 881 | $0 | 5/22/2025 | View on chart |
| EAT | ▲ Buy | Grant | 256 | $0 | 5/8/2025 | View on chart |
| EAT | ▲ Buy | Grant | 218 | $0 | 2/13/2025 | View on chart |
| EAT | ▲ Buy | Grant | 300 | $0 | 11/14/2024 | View on chart |
| EAT | ▲ Buy | Grant | 498 | $0 | 8/29/2024 | View on chart |
| AIZN | ▲ Buy | Grant | 947 | $0 | 5/24/2024 | View on chart |
| EAT | ▲ Buy | Grant | 598 | $0 | 5/9/2024 | View on chart |
| EAT | ▲ Buy | Grant | 777 | $0 | 2/8/2024 | View on chart |
| EAT | ▲ Buy | Grant | 1,037 | $0 | 11/9/2023 | View on chart |
| EAT | ▲ Buy | Grant | 1,069 | $0 | 8/31/2023 | View on chart |
| AIZN | ▲ Buy | Grant | 1,235 | $0 | 5/12/2023 | View on chart |
| EAT | ▲ Buy | Grant | 757 | $0 | 5/11/2023 | View on chart |
| EAT | ▲ Buy | Grant | 676 | $0 | 2/9/2023 | View on chart |
| EAT | ▲ Buy | Grant | 951 | $0 | 11/8/2022 | View on chart |
| EAT | ▲ Buy | Grant | 967 | $0 | 9/8/2022 | View on chart |
| AIZN | ▲ Buy | Grant | 881 | $0 | 5/13/2022 | View on chart |
| EAT | ▲ Buy | Grant | 813 | $0 | 5/12/2022 | View on chart |
| EAT | ▲ Buy | Grant | 664 | $0 | 2/10/2022 | View on chart |
| EAT | ▲ Buy | Grant | 637 | $0 | 11/11/2021 | View on chart |
| EAT | ▲ Buy | Grant | 445 | $0 | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Brinker International (EAT) Gains Attention Amid Restaurant Outlook
Recent articles highlight Brinker International as a trending stock amid a positive outlook for the restaurant sector. Analysts note that the company’s fundamentals are solid, and industry reports suggest continued growth in restaurant sales. The news underscores Brinker’s potential to benefit from broader market trends, though it remains within its 52‑week range.
Brinker International (EAT) Gains Attention Amid Restaurant Outlook. Recent articles highlight Brinker International as a trending stock amid a positive outlook for the restaurant sector. Analysts note that the company’s fundamentals are solid, and industry reports suggest continued growth in restaurant sales. The news underscores Brinker’s potential to benefit from broader market trends, though it remains within its 52‑week range.